Efficacy and Safety of Intratympanic Botulinum Toxin Injection on Middle Ear Myoclonic Tinnitus
Open Access
- 25 July 2025
- journal article
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 403-410
Abstract
Objectives: Investigating the efficacy and safety of intratympanic Botulinum toxin (IT‐BTX) injection as a novel treatment for middle ear myoclonic tinnitus (MEMT). Methods: Medical records and tinnitus questionnaires of the patients with MEMT who underwent IT‐BTX were retrospectively reviewed. The efficacy of IT‐BTX on MEMT as well as its safety were evaluated by audiology tests and tinnitus questionnaires. Results: A total of 57 patients who completed the questionnaires at pre‐ and post‐IT‐BTX were enrolled. Tinnitus handicap inventory (THI) scores decreased significantly from pre‐IT‐BTX (44.31 ± 26.8) to 31.42 ± 23.6 ( p < 0.001), 32.92 ± 24.9 ( p = 0.004), and 25.71 ± 22.9 ( p < 0.001) at 1‐, 3‐, and 6‐months post‐IT‐BTX, respectively. Additionally, visual analog scales (VAS) of loudness (LD), awareness (AW), annoyance (AN), and effect on life (EF) significantly decreased post‐IT‐BTX ( p < 0.05): LD from 4.19 ± 2.4 to 2.47 ± 2.0, 2.89 ± 2.2, and 2.38 ± 1.9 at 1‐, 3‐, and 6‐months; AW from 41.75 ± 29.5 to 24.38 ± 23.3, 26.94 ± 23.3, and 22.10 ± 21.7; AN from 5.00 ± 2.8 to 2.82 ± 2.1, 3.47 ± 2.4, and 2.78 ± 2.2; EF from 4.82 ± 2.8 to 2.89 ± 2.2, 3.28 ± 2.4, and 2.73 ± 2.2 at 1‐, 3‐, and 6‐months post‐IT‐BTX. Notably, 40.3% of the IT‐BTX patients experienced a complete cure of their MEMT symptoms, while 50.8% demonstrated partial resolution after IT‐BTX. There were no side effects or complications after IT‐BTX during their follow‐up period. Comparing delta values between the single injection group and multiple injection group revealed significant differences in VAS LD at the post‐1‐month time point and between the 1‐month and 6‐month intervals. Conclusion: IT‐BTX is an effective, safe treatment for MEMT, significantly improving symptoms without complications, and offers a promising alternative before middle ear tendon resection. Level of Evidence: 4:Keywords
Funding Information
- National Research Foundation of Korea (NRF‐RS‐2024‐00340841)
- National Research Foundation of Korea (NRF‐2021R1F1A1049965)
This publication has 18 references indexed in Scilit:
- Intratympanic Botulinum Toxin Injection as a New Therapeutic Modality for Middle Ear Myoclonic TinnitusOtolaryngology–Head and Neck Surgery, 2023
- Middle ear myoclonus: Systematic review of results and complications for various treatment approachesAmerican Journal of Otolaryngology, 2022
- Long-Term Effects of Middle Ear Tendon Resection on Middle Ear Myoclonic Tinnitus, Hearing, and HyperacusisAudiology and Neurotology, 2017
- Middle Ear Myoclonus Cured by Selective Tenotomy of the Tensor TympaniOtology & Neurotology, 2013
- Clinical characteristics and therapeutic response of objective tinnitus due to middle ear myoclonus: A large case seriesThe Laryngoscope, 2013
- Botox transient treatment of tinnitus due to stapedius myoclonus: Case reportClinical Neurology and Neurosurgery, 2011
- Bilateral Myoclonus of the Tensor Tympani: A Case ReportOtolaryngology–Head and Neck Surgery, 2003
- Management of middle ear myoclonusThe Journal of Laryngology & Otology, 1994
- The supression of palatal (or intra-tympanic) myclonus by tinnitus masking devicesThe Journal of Laryngology & Otology, 1987
- Tinnitus due to Abnormal Contraction of Stapedial MuscleORL, 1974